Blockmir Technology to Selectively Up Regulate Therapeutic Targets and Neutralise Disease-Associated microRNA Activity
Case ID: 068
Web Published: 12/17/2020
Overview
Mirrx Therapeutics A/S is commercializing innovative ”Blockmir” oligonucleotide technology, a proprietary therapeutic paradigm with potential to (i) enhance the protein expression of previously undruggable targets, and (ii) neutralise pathological microRNA expression via selective blockade of microRNA-based gene regulation.
Blockmir
Blockmir drugs are differentiated, and expected to be superior to other technologies designed to enhance protein expression or modulate microRNA activity, benefiting from ease of design, promotion of endogenous, physiological and tissue-specific protein expression, attractive pharmacokinetics and formulation. Having generated exciting proof of principle data, Mirrx is now interested to enter into strategic collaborations to design, develop and commercialise Blockmir therapeutic drugs.
Buy Technology
https://wdemo.technologypublisher.com/files/sites/depositphotos_13404624_s-2019.jpg
Patent Information:
| Title |
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
Patent Status |
| Blockmir Technology to Selectively Up Regulate Therapeutic Targets and Neutralise Disease-Associated microRNA Activit |
Utility |
*United States |
|
9661651456 |
|
|
|
Pending |
Direct Link: https://wdemo.technologypublisher.com/techcase/068